Inquiry Basket
Ac-LEHD-AMC | 292633-16-0
| Catalog Number | A18-0023 |
| Category | Fluorescent Enzyme Substrates |
| Molecular Formula | C33H41N7O11 |
| Molecular Weight | 711.7 |
| Catalog Number | Size | Price | Quantity |
|---|---|---|---|
| A18-0023 | -- | $-- |
- Worldwide Delivery
- Quality Assurance
- 24/7 Customer Service
Product Introduction
Ac-LEHD-AMC is a fluorogenic substrate for caspase-9. Ac-LEHD-AMC is cleaved by caspase-9 to release the fluorescent moiety AMC, which can be used to quantify caspase-9 activity.
Chemical Information |
|
|---|---|
| Synonyms | N-acetyl-L-leucyl-L-α-glutamyl-L-histidyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-L-α-asparagine |
| Purity | ≥95% |
| IUPAC Name | (4S)-4-[[(2S)-2-acetamido-4-methylpentanoyl]amino]-5-[[(2S)-1-[[(2S)-3-carboxy-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid |
| Canonical SMILES | CC1=CC(=O)OC2=C1C=CC(=C2)NC(=O)C(CC(=O)O)NC(=O)C(CC3=CN=CN3)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C |
| InChI | InChI=1S/C33H41N7O11.C2HF3O2/c1-16(2)9-23(36-18(4)41)32(49)38-22(7-8-27(42)43)30(47)39-24(11-20-14-34-15-35-20)33(50)40-25(13-28(44)45)31(48)37-19-5-6-21-17(3)10-29(46)51-26(21)12-19;3-2(4,5)1(6)7/h5-6,10,12,14-16,22-25H,7-9,11,13H2,1-4H3,(H,34,35)(H,36,41)(H,37,48)(H,38,49)(H,39,47)(H,40,50)(H,42,43)(H,44,45);(H,6,7)/t22-,23-,24-,25-;/m0./s1 |
| InChI Key | UOZNIAKIZDCQSH-NATPOTRJSA-N |
- Product Specification
- Application
| Storage | Store at -20°C |
Ac-LEHD-AMC, a synthetic peptide substrate utilized in biochemical research, serves various purposes in scientific exploration. Here are four key applications of Ac-LEHD-AMC:
Caspase Activity Assays: A cornerstone in the realm of apoptotic pathways, Ac-LEHD-AMC is a pivotal tool for assessing caspase-9 activity. Upon cleavage by the active caspase-9, this substrate liberates a fluorescent AMC molecule, offering a measurable signal. This assay plays a critical role in delving into programmed cell death intricacies and screening potential drugs that modulate apoptosis.
Drug Screening: In the domain of pharmaceutical research, Ac-LEHD-AMC serves as a linchpin in the identification and evaluation of caspase-9 inhibitors. High-throughput screening assays leveraging this substrate can swiftly gauge the effectiveness of novel drug candidates. This contributes significantly to uncovering innovative therapeutic agents tailored to combat apoptosis-related afflictions like cancer.
Biomedical Research: Ac-LEHD-AMC is a prized asset for researchers aiming to unravel the involvement of caspase-9 in diverse diseases ranging from neurodegenerative disorders to cardiovascular conditions. By monitoring caspase activity, scientists delve into disease mechanisms and the impact of apoptosis on disease progression. This knowledge forms the bedrock for crafting precision interventions targeted at specific ailments.
Pathway Elucidation: A key ally in unraveling apoptosis pathways, Ac-LEHD-AMC facilitates precise measurement of caspase-9 activity within cellular milieus. By employing this substrate, researchers can track real-time fluctuations in caspase activity across varied experimental settings. This aids in deciphering the intricate web of signaling pathways governing cell survival and demise, shedding light on the mysteries of life processes.
Computed Properties | |
|---|---|
| XLogP3 | -0.3 |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 18 |
| Exact Mass | 711.28640515 g/mol |
| Monoisotopic Mass | 711.28640515 g/mol |
| Topological Polar Surface Area | 275Ų |
| Heavy Atom Count | 51 |
| Formal Charge | 0 |
| Complexity | 1370 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
Patents
| Publication Number | Title | Priority Date |
|---|---|---|
| EP-3929209-A1 | Vasopressin-2 receptor antagonist peptides and uses thereof | 2020-06-24 |
| WO-2019227240-A1 | Methods for treating cancer with acyldepsipeptide analogs | 2018-06-01 |
| CA-3102215-A1 | Methods for treating cancer with acyldepsipeptide analogs | 2018-06-01 |
| US-2021122780-A1 | Compositions for the prevention and treatment of parkinson's disease | 2018-03-29 |
| US-2022267367-A1 | Compositions for the prevention and treatment of parkinson's disease | 2018-03-29 |
Applications of Fluorescent Probes & Dyes
Get More Product Details?
